CBIO
Crescent Biopharma, Inc.
$18.02
-4.35
(-19.45%)
Mkt Cap
485.69M
Volume
732,536
52W Range
8.72-29
Sector
Healthcare
Beta
1.03
EPS (TTM)
-699.21
P/E Ratio
-8.24
Revenue (TTM)
41.41M
Rev Growth (5Y)
+1.3%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
$6.82
Overvalued · Strong
158.3% above fair value
AlphaQuality · Grade · Gated
F
Stable Earnings Power
22.6 / 100 pillar composite (overridden)
Company Description
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.84M | 0 | 10,000 | 75,000 | 1.16M | 10.16M | 0 | 0 | 0 | 18,500 | 20.07M | 15.03M |
| Net Income | (149.94M) | (71.47M) | (36.90M) | (46.69M) | (63.43M) | (51.03M) | (54.12M) | (48.27M) | (33.28M) | (31.81M) | (12.77M) | (11.12M) |
| EPS | 0.06 | -0.59 | -0.58 | -0.89 | -1.23 | -1.12 | -1.34 | -1.18 | -1.13 | -1.50 | -0.67 | -0.60 |
| Free Cash Flow | (72.45M) | (31.11M) | (34.90M) | (46.54M) | (57.50M) | (39.31M) | (52.13M) | (43.46M) | (30.06M) | (30.44M) | N/A | N/A |
| FCF / Share | -0.70 | -0.48 | -0.55 | -0.89 | -1.12 | -0.86 | -1.21 | -1.06 | -1.02 | -1.43 | N/A | N/A |
| Operating CF | (71.53M) | (31.10M) | (34.88M) | (46.46M) | (57.49M) | (39.24M) | (51.98M) | (43.33M) | (29.77M) | (29.73M) | N/A | N/A |
| Total Assets | 240.29M | 35.62M | 45.32M | 51.81M | 94.35M | 142.83M | 167.97M | 214.84M | 128.58M | 42.39M | N/A | N/A |
| Total Debt | 1.64M | 37.48M | 808,402 | 918,555 | 1.92M | 2.82M | 3.62M | 0 | 0 | 0 | N/A | N/A |
| Cash & Equiv | 213.19M | 34.77M | 41.79M | 47.87M | 90.25M | 137.04M | 158.20M | 209.92M | 123.92M | 40.04M | N/A | N/A |
| Book Value | 203.01M | (15.48M) | 38.41M | 42.93M | 81.60M | 128.22M | 154.20M | 205.46M | 119.70M | 35.30M | N/A | N/A |
| Return on Equity | -0.74 | N/A | -0.96 | -1.09 | -0.78 | -0.40 | -0.35 | -0.23 | -0.28 | -0.90 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 10.84M | 30.56M | 0 | 0 | 0 | 0 | 0 | 0 | 10,000 | 0 | 0 |
| Net Income | 0 | (92.40M) | (24.61M) | (21.79M) | (2.34M) | (7.22M) | (9.82M) | (10.10M) | (10.74M) | (9.08M) | (9.20M) | (8.26M) |
| EPS | -699.31 | 0.34 | 0.04 | -0.28 | -0.04 | -0.11 | -0.15 | -0.16 | -0.17 | -0.14 | -0.14 | -0.13 |
| Free Cash Flow | (9.08M) | 22.13M | (18.11M) | (22.30M) | (5.11M) | (3.70M) | 19.41M | (8.90M) | (10.52M) | (7.62M) | (8.69M) | (6.99M) |
| FCF / Share | -0.03 | 0.21 | -0.20 | -0.29 | -0.08 | -0.06 | 0.30 | -0.14 | -0.16 | -0.12 | -0.14 | -0.11 |
| Operating CF | (8.94M) | 22.21M | (17.52M) | (22.16M) | (5.11M) | (3.70M) | 19.40M | (8.89M) | (10.51M) | (7.61M) | (8.68M) | (6.97M) |
| Total Assets | 199.13M | 240.29M | 138.27M | 157.43M | 5.99M | 11.09M | 15.70M | 24.42M | 34.20M | 45.32M | 53.20M | 61.82M |
| Total Debt | 1.54M | 1.64M | 3.06M | 3.08M | 0 | 66,844 | 262,133 | 448,775 | 630,827 | 808,402 | 1.01M | 1.27M |
| Cash & Equiv | 189.16M | 213.19M | 133.26M | 152.65M | 5.61M | 10.72M | 14.39M | 22.39M | 31.28M | 41.79M | 49.41M | 58.04M |
| Book Value | 183.85M | 203.01M | 116.64M | 139.25M | 3.38M | 5.31M | 11.38M | 20.06M | 28.91M | 38.41M | 46.55M | 54.80M |
| Return on Equity | N/A | -0.46 | -0.21 | -0.16 | -0.69 | -1.36 | -0.86 | -0.50 | -0.37 | -0.24 | -0.20 | -0.15 |
CBIO News
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives $28.00 Average Target Price from Brokerages
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Crescent Biopharma to Present at March Investor Conferences
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026